Angeles Wealth Management LLC Takes $245,000 Position in DexCom, Inc. (NASDAQ:DXCM)

Angeles Wealth Management LLC bought a new position in DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, Holdings Channel.com reports. The firm bought 3,145 shares of the medical device company’s stock, valued at approximately $245,000.

Several other hedge funds also recently made changes to their positions in DXCM. Versant Capital Management Inc bought a new stake in DexCom in the 4th quarter worth $25,000. Riverview Trust Co raised its stake in shares of DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after acquiring an additional 232 shares during the last quarter. Heck Capital Advisors LLC purchased a new stake in shares of DexCom during the fourth quarter worth about $38,000. MassMutual Private Wealth & Trust FSB grew its stake in shares of DexCom by 46.7% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock worth $65,000 after purchasing an additional 265 shares during the last quarter. Finally, RPg Family Wealth Advisory LLC purchased a new position in DexCom during the 3rd quarter valued at about $57,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $88.27 on Tuesday. The business has a fifty day moving average price of $81.76 and a 200-day moving average price of $75.11. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The company has a market capitalization of $34.48 billion, a PE ratio of 52.86, a PEG ratio of 2.26 and a beta of 1.14. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00.

Insider Activity at DexCom

In other news, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the sale, the executive vice president now owns 83,526 shares in the company, valued at $7,259,244.66. This represents a 2.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 42,342 shares of company stock valued at $3,628,069. 0.30% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research firms have weighed in on DXCM. Raymond James dropped their price objective on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a report on Friday, October 25th. Sanford C. Bernstein lifted their price target on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Oppenheimer dropped their target price on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Finally, Royal Bank of Canada reduced their price target on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $98.41.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.